Testosterone and lifestyle diseases

Česká verzia

Authors: L. Stárka
Authors place of work: Ředitel: doc. MUDr. Vojtěch Hainer, CSc. ; Endokrinologický ústav, Praha
Published in the journal: Prakt. Lék. 2010; 90(11): 636-639
Category: Reviews

Summary

Subnormal levels of testosterone are frequently found in men of advanced age. Hypogonadal men have lower life expectancy than men with full androgenisation, and cardiovascular disease, obesity or diabetes is often associated with hypotestosteronemia. Low testosterone level is a risk factor for these diseases. However, it is still not clear whether testosterone deficiency is a cause or consequence of atherosclerosis or metabolic syndrome. A handful of symptoms and metabolic parameters present in hypogonadal men can be ameliorated by testosterone supplementation. Testosterone has a beneficial effect on cardiovascular risk factors, but it is not clear whether it reduces mortality.

Key words:
testosterone, cardiovascular disease, obesity, metabolic syndrome, diabetes mellitus.

Zdroje

1. Casson, P.R., Toth, M.J., Johnson, J.V. et al. Correlation of serum androgens with anthropometric and metabolic indices in healthy, nonobese postmenopausal women. J. Clin. Endocrinol. Metab. 2010, 95, p. 4276-4282.

2. Caminiti, G., Volterrani, M., Iellamo, F. et al. Effect of long-acting testostereone treatment on functional exercise capacity, skeletal muscle performace, insulin resistance, and baroreflex sensitivity in elderly patients with chronic heart failure. A double-blind, placebo-controlled, randomised study. J. Am. Coll. Cardiol. 2009, 54, p. 919-927.

3. Jones, T.H. Testosterone deficiency: a risk actor for cardiovascular disease? Trends Endocrinol. Metab. 2010, 21, p. 496-503.

4. Kelleher, S., Conway, A.J., Handelsman, D.J. Blood testosterone threshold for androgen deficiency symptoms. J. Clin. Endocrinol. Metab. 2004, 89, p. 3813-387.

5. Kupelian, V., Page, S.T., Araujo, A.B. et al. Low sex hormone binding globulin, total testosterone, and symptomatic androgen deficiency are associated with the decelopment of the metabolic syndrome, in no-obese men. J. Clin. Endocrinol. Metab., 2006, 91, p. 843-850.

6. Laughlin, G.A., Barret-Connor, E., Bergstrom. J. Low serum testosterone and mortality in older men. J. Clin. Endocrin. Metab. 2008, 93, p. 68-75.

7. Mathur. A., Malkin, C., Saeed, B. et al. Long-term benefits of testosterone replacement therapy on angina treshold and atheroma in men. Eur. J. Endocrinol., 2009, 161, p. 443-449.

8. Miner, M., Canty, D.J., Shabsigh, R. Testosterone replacement therapy in hypogonadal men: assessing benefits, risks, and best practices. Postgrad. Med., 2008, 120, p. 130-153.

9. Nettleship, J.E., Jones, R.D., Channer, K.S., Jones TH. Testosterone and coronary artery disease. Front. Horm. Res. 2009, 37, p. 91-107.

10. Sievers, C., Klotsche, J., Pieper, L. et al. Low testosterone leevels predict all-cause mortality and cardiovascular events in women: a prospective cohort study in German primary care patients. Eur. J. Endocrinol. 2010, 163, p. 699-708.

11. Stanworth, R.D., Jones, T.H. Testosterone in obezity, metabolic syndrome and type 2 diabetes. Front. Horm. Res. 2009, 37, p. 74-90.

12. Tajar, A., Forti, G., O’Neill, T.W. et al. Characteristics of secondary, primary, and compensated hypogonadism in aging men: Evidence from the European Male Ageing Study. J. Clin. Endocrinol. Metab. 2010. 95, p. 1810-18.

13. Vrbíková, J., Stanická, S., Vondra, K., et al. Insulin resistance in endocrine disorders. In: Insulin Resistance New Research. Ed. E.B. Yao, Nova Sci. Publ. Inc, 2009, p. 1-47.

14. Webb, C.M., Collins, P. Testosterone and coronary artery disease in men. Maturitas, 2010, 67, p. 15-19.

15. Yeap, B.B., Chubb, S.A., Hyde, Z. et al. Lower serum testosterone is independently associated with insulin resistance in non-diabetic older men. The Health In Men Study. Eur. J. Endocrinol., 2009, 161, p. 591-8.

16. Zitzmann, M., Faber, S., Nieschlag, E. Association of specific symptoms and metabolic risks with serum testosterone in older men. J. Clin. Endocrinol. Metab., 2006,. 91, p. 4335-4343.